D-1040-2017 Class II Terminated

Recalled by Fusion IV Pharmaceuticals, Inc. Dba Axia Pharmaceutical — Los Angeles, CA

FDA drug recall D-1040-2017 was initiated by Fusion IV Pharmaceuticals, Inc. Dba Axia Pharmaceutical on Jul 12, 2017 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Jan 14, 2019). Affected quantity: 120 vials.

Recall details

Product Type
Drugs
Report Date
Aug 9, 2017
Initiation Date
Jul 12, 2017
Termination Date
Jan 14, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
120 vials

Product description

Testosterone Cypionate + Progesterone, 200 mg/ 2.5 mg/mL ,10 mL amber glass vials, Rx Only, Compounded by AXIA Pharmaceutical, Los Angeles, CA 90025

Reason for recall

CGMP Deviations

Distribution pattern

There were only one customer in California

Code information

Lot # 03022017+44906; BUD 08/29/17

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1040-2017
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1040-2017. Report a data issue: hello@regdatalab.com.